EANS-News: AGENNIX AG Successfully Completes Rights Offering in the Amount of Approximately Euro 27.5 Million

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital measures

Planegg/Munich (Germany), December 8, 2011 (euro adhoc) - Company
raises approximately Euro 11.3 million in cash and Euro 16.2 million
from the conversion to equity of an existing loan plus interest

Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX/ISIN
DE000A1A6XX4) today announced that the Company has successfully
completed its rights offering in which shareholders subscribed to all
of the offered 9,319,504 new no-par value bearer shares by the end of
the subscription period on December 6, 2011. In this transaction,
Agennix raised approximately Euro 11.3 million from subscriptions
against cash and approximately Euro 16.2 million from the conversion
to equity of an existing loan plus interest. The subscription price
was Euro 2.95 per share, an approximately 4% discount to the XETRA
closing price of Euro 3.06 per Agennix AG share on the Frankfurt
Stock Exchange on November 16, 2011, the date of the announcement of
the rights offering. The Management Board, with the approval of the
Supervisory Board, has therefore resolved to increase the Company's
share capital from Euro 41,937,776 to Euro 51,257,280 by issuing
9,319,504 new shares.

Torsten Hombeck, Ph.D., Chief Financial Officer and Spokesperson of
the Management Board, said: "We are very pleased to have been able to
successfully complete this financing, especially in such a
challenging market environment, and are very grateful for the strong
support of dievini, our major shareholder. We now believe that we
have sufficient cash to fund ongoing operations into 2013,
strengthening our financial position post our upcoming major data
readouts."

Dr. Hombeck continued: "The year 2012 will be an exciting one for
Agennix. We expect to see top-line results from the talactoferrin
Phase III FORTIS-M trial in non-small cell lung cancer in the second
quarter of 2012, and, should the results so warrant, would plan to
then file for regulatory approval. We also expect to see top-line
results from the Phase II part of the talactoferrin OASIS trial in
severe sepsis in the second quarter of 2012 and hope to then initiate
the Phase III part of that trial."

The capital increase was a mixed capital increase of cash and
contribution in kind. The contribution in kind involved the
contribution by the Company's major shareholder, dievini Hopp BioTech
holding GmbH & Co. KG (dievini), of the Euro 15.0 million loan made
to Agennix in July 2010, plus approximately Euro 1.2 million in
accrued interest. As previously agreed, dievini exercised all of its
subscription rights in the rights offering with respect to shares
held by it, which represented the principal amount of the loan plus
the accrued interest. As a result of this transaction, Agennix has no
further obligations regarding this loan. In addition, dievini
participated in the oversubscription offering. Following the
completion of the offering, dievini will hold approximately 65% of
shares outstanding in Agennix.

The entry of the capital increase in the commercial register is
expected to occur on or around December 9, 2011. The new shares are
expected to begin trading in the regulated market in the Prime
Standard of the Frankfurt Stock Exchange on or around December 14,
2011 under the existing stock identification number AGX/ISIN
DE000A1A6XX4.

Kempen & Co N.V. served as the sole global coordinator for the
transaction.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral
immunotherapy that has demonstrated activity in randomized,
double-blind, placebo-controlled Phase II studies in non-small cell
lung cancer and in severe sepsis. Talactoferrin is currently in Phase
III clinical trials in non-small cell lung cancer and in a Phase
II/III trial in severe sepsis. Other clinical development programs
include RGB-286638, a multi-targeted kinase inhibitor in Phase I
testing for cancer, and a topical gel form of talactoferrin for
diabetic foot ulcers. Agennix's registered seat is in Heidelberg,
Germany. The Company has three sites of operation: Planegg/Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional
information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG,
including statements about the Company's future cash position. Such
statements are based on current expectations and are subject to risks
and uncertainties, many of which are beyond our control, that could
cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

This press release is not for distribution, directly or indirectly,
in or into the United States (including its territories and
possessions, any State of the United States and the District of
Columbia). These materials do not constitute or form a part of any
offer or solicitation to purchase or subscribe for securities in the
United States of America. The shares in Agennix AG (the "Shares")
mentioned herein may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S.
Securities Act of 1933, as amended (the "Securities Act").

The Shares have not been, and will not be, registered under the
Securities Act and will not be offered or sold in the United States,
except on the basis of applicable exemptions from registration. There
will be no public offering of securities in the United States or
elsewhere.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English